GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients

GSK looks to compete with Pfizer and Moderna in the 18-49 age group of the RSV vaccine market in the US.

Jul 15, 2025 - 06:00
GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients
GSK looks to compete with Pfizer and Moderna in the 18-49 age group of the RSV vaccine market in the US.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow